CL2015000097A1 - Agentes de unión de proteína de r-espondina humana (rspo3) y usos de los mismos. - Google Patents
Agentes de unión de proteína de r-espondina humana (rspo3) y usos de los mismos.Info
- Publication number
- CL2015000097A1 CL2015000097A1 CL2015000097A CL2015000097A CL2015000097A1 CL 2015000097 A1 CL2015000097 A1 CL 2015000097A1 CL 2015000097 A CL2015000097 A CL 2015000097A CL 2015000097 A CL2015000097 A CL 2015000097A CL 2015000097 A1 CL2015000097 A1 CL 2015000097A1
- Authority
- CL
- Chile
- Prior art keywords
- rspo3
- human
- binding agents
- protein binding
- spondin protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261671421P | 2012-07-13 | 2012-07-13 | |
US201361753184P | 2013-01-16 | 2013-01-16 | |
US201361789156P | 2013-03-15 | 2013-03-15 | |
US201361826747P | 2013-05-23 | 2013-05-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2015000097A1 true CL2015000097A1 (es) | 2015-07-10 |
Family
ID=49914164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2015000097A CL2015000097A1 (es) | 2012-07-13 | 2015-01-13 | Agentes de unión de proteína de r-espondina humana (rspo3) y usos de los mismos. |
Country Status (24)
Country | Link |
---|---|
US (3) | US9181333B2 (es) |
EP (1) | EP2872175A4 (es) |
JP (1) | JP6335896B2 (es) |
KR (1) | KR20150036603A (es) |
CN (1) | CN104854132A (es) |
AU (1) | AU2013289990B2 (es) |
BR (1) | BR112015000776A2 (es) |
CA (1) | CA2878868A1 (es) |
CL (1) | CL2015000097A1 (es) |
EA (1) | EA032038B1 (es) |
EC (1) | ECSP15005280A (es) |
HK (1) | HK1208687A1 (es) |
IL (1) | IL236617A0 (es) |
IN (1) | IN2015KN00350A (es) |
MX (1) | MX2015000565A (es) |
NI (1) | NI201500002A (es) |
NZ (1) | NZ704269A (es) |
PE (1) | PE20150360A1 (es) |
PH (1) | PH12015500084A1 (es) |
SG (1) | SG11201500233PA (es) |
TW (2) | TW201906861A (es) |
UA (1) | UA117659C2 (es) |
WO (1) | WO2014012007A2 (es) |
ZA (1) | ZA201500872B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA018260B1 (ru) | 2006-09-29 | 2013-06-28 | Онкомед Фармасьютикалз, Инк. | Антитела к дельта-подобному лиганду 4 человека и их применение |
EP3424529A1 (en) | 2007-07-02 | 2019-01-09 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
WO2012174446A1 (en) | 2011-06-17 | 2012-12-20 | President And Fellows Of Harvard College | Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer |
US8802097B2 (en) | 2011-07-15 | 2014-08-12 | Oncomed Pharmaceuticals, Inc. | Anti-RSPO1 antibodies |
MX2015000565A (es) | 2012-07-13 | 2015-04-10 | Oncomed Pharm Inc | Agentes de union de proteina de r-espondina humana (rspo3) y usos de los mismos. |
CA2925598A1 (en) * | 2013-10-18 | 2015-04-23 | Genentech, Inc. | Anti-rspo antibodies and methods of use |
CN106488775A (zh) | 2014-07-11 | 2017-03-08 | 基因泰克公司 | Notch途径抑制 |
US10064937B2 (en) | 2014-09-16 | 2018-09-04 | Oncomed Pharmaceuticals, Inc. | Treatment of dermal fibrosis |
MA41123A (fr) * | 2014-12-02 | 2017-10-10 | Oncomed Pharm Inc | Polythérapie pour le traitement du cancer |
WO2017040660A1 (en) * | 2015-08-31 | 2017-03-09 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
CN106913880B (zh) * | 2015-12-24 | 2021-02-12 | 上海交通大学 | 一种含有rspo1的靶向给药系统及其制备与应用 |
CN105925576B (zh) * | 2016-03-24 | 2018-04-20 | 嘉兴市第一医院 | 针对哺乳动物R‑Spondin3基因靶点的小干扰RNA、短发卡RNA及载体和应用 |
US20170319688A1 (en) * | 2016-04-14 | 2017-11-09 | Genentech, Inc. | Anti-rspo3 antibodies and methods of use |
WO2018035210A1 (en) * | 2016-08-17 | 2018-02-22 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with an rspo antagonist |
KR20200096275A (ko) | 2017-12-07 | 2020-08-11 | 내셔날 헬스 리서치 인스티튜트 | 항-rspo3 항체 |
CN110339364B (zh) * | 2018-04-02 | 2021-02-12 | 上海邦耀生物科技有限公司 | Lgr4/rspo阻断剂与抗免疫检查点抑制剂联合用于肿瘤的免疫治疗 |
CN110467663B (zh) * | 2019-06-18 | 2022-05-10 | 华南农业大学 | Rspo3基因在母猪卵巢颗粒细胞中的应用 |
KR102554222B1 (ko) * | 2023-03-21 | 2023-07-11 | 순천향대학교 산학협력단 | 신규한 항-인간 알스폰딘3 항체 및 이의 용도 |
CN116769030B (zh) * | 2023-08-21 | 2023-10-20 | 成都大熊猫繁育研究基地 | 一种大熊猫松弛素3单克隆抗体及其杂交瘤细胞株和应用 |
Family Cites Families (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US20070124581A1 (en) | 1992-05-17 | 2007-05-31 | Reena Khare | Cell adhesion and extracellular matrix proteins |
WO1998049302A1 (en) | 1997-04-25 | 1998-11-05 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
US6004528A (en) | 1997-09-18 | 1999-12-21 | Bergstein; Ivan | Methods of cancer diagnosis and therapy targeted against the cancer stemline |
CA2304828A1 (en) | 1997-09-24 | 1999-04-01 | Merck & Co., Inc. | G-protein coupled glycoprotein hormone receptor hg38 |
US20020065394A1 (en) | 1998-03-18 | 2002-05-30 | Kenneth Jacobs | Secreted proteins and polynucleotides encoding them |
ES2332025T3 (es) | 1998-03-26 | 2010-01-22 | The Board Of Trustees Of The Leland Stanford Junior University | Nuevos receptores de mamiferos acoplados a la proteina g que tienen regiones extracelulares de repeticion ricas en leucina. |
US6485972B1 (en) | 1998-10-15 | 2002-11-26 | President And Fellows Of Harvard College | WNT signalling in reproductive organs |
US20030166047A1 (en) | 1999-05-06 | 2003-09-04 | Millennium Pharmaceuticals, Inc. | Lgr6 nucleic acids and uses thereof |
AU6117000A (en) | 1999-07-26 | 2001-02-13 | Genentech Inc. | Novel polynucleotides and method of use thereof |
US6824973B2 (en) | 2000-02-03 | 2004-11-30 | Kirin Beer Kabushiki Kaisha | Method of promoting stem cell proliferation or survival by contacting a cell with a stem cell factor-like polypeptide |
WO2001057190A2 (en) | 2000-02-03 | 2001-08-09 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
CA2403817C (en) | 2000-03-31 | 2012-05-29 | The General Hospital Corporation | Methods of modulating hair growth |
JP2003530124A (ja) | 2000-04-05 | 2003-10-14 | 麒麟麦酒株式会社 | 新規幹細胞成長因子様ポリペプチドおよびポリヌクレオチドに関する方法および物質 |
EP1156062A1 (en) | 2000-05-12 | 2001-11-21 | GPC Biotech AG | Immunomodulatory human MHC class II antigen-binding peptides/proteins |
AU2001263006A1 (en) | 2000-05-18 | 2001-11-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
WO2001092297A2 (en) | 2000-05-30 | 2001-12-06 | Bayer Aktiengesellschaft | Regulation of human lgr4-like g protein-coupled receptor |
US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
US6768004B2 (en) * | 2001-01-11 | 2004-07-27 | Mueller Sybille | Nucleotide sequences encoding variable regions of heavy and light chains of monoclonal antibody 1F7, an anti-idiotypic antibody reactive with anti-HIV antibodies |
US20040077048A1 (en) | 2002-01-30 | 2004-04-22 | Warren Bridget A. | Protein modification and maintenance molecules |
US20100292155A1 (en) | 2001-03-05 | 2010-11-18 | Arca Biopharma, Inc. | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
US7411052B2 (en) | 2001-03-05 | 2008-08-12 | Nuvelo, Inc. | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
US20030032034A1 (en) | 2001-03-05 | 2003-02-13 | Tang Y. Tom | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
AU2002304249A1 (en) | 2001-06-11 | 2002-12-23 | Kirin Beer Kabushiki Kaisha | Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and dna coding for the same |
DE60233509D1 (de) | 2001-06-20 | 2009-10-08 | Fibron Ltd | Fgfr3 blockierende antikörper, verfahren zum screening darauf und verwendungen davon |
US20030022217A1 (en) | 2001-07-02 | 2003-01-30 | Pe Corporation (Ny) | Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
EP2228443A1 (en) | 2001-08-30 | 2010-09-15 | ARCA biopharma, Inc. | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
JP2005514917A (ja) | 2001-10-03 | 2005-05-26 | インサイト・ゲノミックス・インコーポレイテッド | 分泌タンパク質 |
US20070237770A1 (en) * | 2001-11-30 | 2007-10-11 | Albert Lai | Novel compositions and methods in cancer |
US20040197778A1 (en) | 2002-12-26 | 2004-10-07 | Sagres Discovery, Inc. | Novel compositions and methods in cancer |
CA2469204A1 (en) | 2001-12-07 | 2003-06-19 | Regents Of The University Of Michigan | Prospective identification and characterization of breast cancer stem cells |
EP1504099A4 (en) | 2001-12-10 | 2006-05-10 | Nuvelo Inc | NEW NUCLEIC ACIDS AND POLYPEPTIDES |
US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
US7439332B2 (en) | 2002-04-26 | 2008-10-21 | Kirin Pharma Kabushiki Kaisha | Polypeptide having an activity to support proliferation or survival of hematopoietic stem or progenitor cells |
EP1380644A1 (en) | 2002-07-08 | 2004-01-14 | Kylix B.V. | The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role |
GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
WO2004074436A2 (en) | 2003-02-19 | 2004-09-02 | Incyte Corporation | Methods of use of a gpcr in the diagnosis and treatment of colon and lung cancer |
US20050003405A1 (en) | 2003-04-30 | 2005-01-06 | Hua-Chien Chen | Treatment and diagnostics of cancer |
EP2003196A3 (en) | 2003-06-09 | 2009-01-07 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing cancer |
WO2005110009A2 (en) | 2003-07-22 | 2005-11-24 | Immunex Corporation | COMPOSITIONS AND METHODS RELATING TO TSP-30a, b, c AND d |
DE10339820A1 (de) | 2003-08-22 | 2005-03-17 | Hinzmann, Bernd, Dr. | Verwendung von an GPR49 bindenden Substanzen zur Diagnose und Behandlung von Krebs |
US9046537B2 (en) | 2003-09-22 | 2015-06-02 | Enzo Biochem, Inc. | Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain |
EP1673475B1 (en) | 2003-10-10 | 2010-04-28 | Deutsches Krebsforschungszentrum | Compositions for diagnosis and therapy of diseases associated with aberrant expression of futrins (r-spondins) and/or wnt |
WO2005040828A2 (en) | 2003-10-24 | 2005-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49) |
US20050256036A1 (en) | 2004-01-27 | 2005-11-17 | Boyle Bryan J | Gastrointestinal proliferative factor and uses thereof |
WO2005074633A2 (en) | 2004-02-03 | 2005-08-18 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
EP1725585A2 (en) | 2004-03-10 | 2006-11-29 | Lonza Ltd | Method for producing antibodies |
CA2579142A1 (en) | 2004-09-13 | 2006-03-23 | Macrogenics, Inc. | Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof |
WO2006067122A2 (en) | 2004-12-20 | 2006-06-29 | Crucell Holland B.V. | Binding molecules capable of neutralizing west nile virus and uses thereof |
US7439327B2 (en) | 2005-01-18 | 2008-10-21 | Nuvelo, Inc. | Stem cell factor-like proteins and uses thereof |
AU2006235258A1 (en) | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | Cancer-related genes |
JP2009502737A (ja) | 2005-07-26 | 2009-01-29 | キリンファーマ株式会社 | R−スポンジンを含有する抗腫瘍薬 |
WO2007030290A2 (en) | 2005-09-07 | 2007-03-15 | Maine Medical Center Research | Cristin/r-spondin ligands active in the wnt signaling pathway and methods, compositions and kits relating thereto |
CA2623413A1 (en) | 2005-10-07 | 2007-09-07 | Nuvelo, Inc. | Stem cell factor-like protein scfa1 and uses thereof |
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
JP5129149B2 (ja) | 2005-10-31 | 2013-01-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 癌を処置および診断するための組成物および方法 |
GB0603683D0 (en) | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
BRPI0712223A2 (pt) | 2006-06-02 | 2012-07-10 | Aveo Pharmaceuticals Inc | proteìnas de ligação ao fator de crescimento de hepatócito (hgf) |
EP2361934A3 (en) | 2006-06-02 | 2011-11-02 | Aveo Pharmaceuticals, Inc. | Hepatocyte growth factor (HGF) binding proteins |
ES2413087T3 (es) | 2006-06-13 | 2013-07-15 | Oncomed Pharmaceuticals, Inc. | Composiciones y métodos para el diagnóstico y tratamiento del cáncer |
USRE47123E1 (en) | 2006-07-18 | 2018-11-13 | Sanofi | EPHA2 receptor antagonist antibodies |
JP2008044926A (ja) | 2006-08-14 | 2008-02-28 | Trustees Of Columbia Univ In The City Of New York | Wnt信号伝達に関係した分泌タンパク質 |
EA018260B1 (ru) | 2006-09-29 | 2013-06-28 | Онкомед Фармасьютикалз, Инк. | Антитела к дельта-подобному лиганду 4 человека и их применение |
PL2081586T5 (pl) | 2006-10-20 | 2019-04-30 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Rspondyny jako modulatory angiogenezy i waskulogenezy |
WO2008075796A1 (ja) | 2006-12-21 | 2008-06-26 | Kyowa Hakko Kirin Co., Ltd. | 血球回復促進剤 |
WO2008088524A2 (en) | 2006-12-28 | 2008-07-24 | Nuvelo, Inc. | Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor |
KR20100044160A (ko) | 2007-06-12 | 2010-04-29 | 와이어쓰 엘엘씨 | 항-cd20 치료 조성물 및 방법 |
EP3424529A1 (en) | 2007-07-02 | 2019-01-09 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
CA2700257A1 (en) | 2007-10-02 | 2009-04-09 | Hartmut Land | Methods and compositions related to synergistic responses to oncogenic mutations |
US20120082659A1 (en) | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
CN102112492B (zh) | 2007-11-14 | 2015-02-25 | 中外制药株式会社 | 使用抗gpr49抗体的癌症的诊断和治疗 |
US8187601B2 (en) | 2008-07-01 | 2012-05-29 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (FGFR3) binding proteins |
WO2010016766A2 (en) | 2008-08-08 | 2010-02-11 | Koninklijke Nederlandse Akademie Van Wetenschappen | Antibodies recognizing endogenous human lgr5 and/or lgr6 |
US9309312B2 (en) * | 2008-10-31 | 2016-04-12 | Toray Industries, Inc. | Immunoassay method for human CXCL1 protein |
WO2010121923A1 (en) | 2009-04-15 | 2010-10-28 | Deutsches Krebsforschungszentrum | Rspondin-3 inhibition in bone disorders |
EP3505636A1 (en) * | 2009-04-27 | 2019-07-03 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
WO2010129284A1 (en) | 2009-04-27 | 2010-11-11 | The Trustees Of The University Of Pennsylvania | Inhibition of hair follicle growth by the wnt inhibitor dkk1 |
EP2442798A4 (en) | 2009-06-18 | 2013-03-13 | Wyeth Llc | LYOPHILIZED FORMULATIONS FOR SMALL-SCALE MODULAR IMMUNOPHARMACEUTICAL AGENTS |
US8318162B2 (en) * | 2009-07-16 | 2012-11-27 | Xoma Technology Ltd. | Antibodies to high molecular weight melanoma associated antigen |
US8709424B2 (en) | 2009-09-03 | 2014-04-29 | Merck Sharp & Dohme Corp. | Anti-GITR antibodies |
EP2977060A1 (en) | 2009-12-23 | 2016-01-27 | Deutsches Krebsforschungszentrum | Receptors of rspo2 and rspo3 |
US8663950B2 (en) | 2010-01-11 | 2014-03-04 | Arizona Board Of Regents | Production of a monoclonal antibody therapeutic against west nile virus in plants |
KR20120117931A (ko) | 2010-02-12 | 2012-10-24 | 온코메드 파마슈티칼스, 인크. | 폴리펩타이드를 발현하는 세포를 확인 및 분리하는 방법 |
EP2659005A4 (en) * | 2010-12-28 | 2016-08-24 | Caris Mpi Inc | MOLECULAR PROFILING OF CANCER |
GB201106395D0 (en) | 2011-04-14 | 2011-06-01 | Hubrecht Inst | Compounds |
MX352599B (es) * | 2011-04-28 | 2017-11-30 | Sbi Biotech Co Ltd | Anticuerpos anti-receptor tipo proteina-tirosina-fosfatasa sigma humano. |
US8802097B2 (en) | 2011-07-15 | 2014-08-12 | Oncomed Pharmaceuticals, Inc. | Anti-RSPO1 antibodies |
CN109111523B (zh) | 2011-10-14 | 2022-06-07 | 诺华股份有限公司 | 用于Wnt途径相关疾病的抗体和方法 |
AU2012332588B2 (en) | 2011-11-01 | 2017-09-07 | Bionomics, Inc. | Methods of blocking cancer stem cell growth |
US9220774B2 (en) | 2011-11-01 | 2015-12-29 | Bionomics Inc. | Methods of treating cancer by administering anti-GPR49 antibodies |
KR102148303B1 (ko) | 2012-02-11 | 2020-08-26 | 제넨테크, 인크. | R-스폰딘 전위 및 그의 사용 방법 |
AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
MX2015000565A (es) | 2012-07-13 | 2015-04-10 | Oncomed Pharm Inc | Agentes de union de proteina de r-espondina humana (rspo3) y usos de los mismos. |
AU2014248568B2 (en) | 2013-03-12 | 2017-07-13 | Curegenix, Inc. | Compounds for treatment of cancer |
EP3006942A4 (en) | 2013-05-30 | 2016-11-30 | Order Made Medical Res Inc | REAGENT WITH ANTI-LGR6 ANTIBODIES FOR THE DETECTION AND DIAGNOSIS OF CANCER |
CA2925598A1 (en) | 2013-10-18 | 2015-04-23 | Genentech, Inc. | Anti-rspo antibodies and methods of use |
MA41123A (fr) | 2014-12-02 | 2017-10-10 | Oncomed Pharm Inc | Polythérapie pour le traitement du cancer |
US9777052B2 (en) | 2014-12-02 | 2017-10-03 | The Board Of Regents Of The University Of Oklahoma | R-spondin variants, compositions, and methods of use |
-
2013
- 2013-07-12 MX MX2015000565A patent/MX2015000565A/es unknown
- 2013-07-12 NZ NZ704269A patent/NZ704269A/en not_active IP Right Cessation
- 2013-07-12 BR BR112015000776A patent/BR112015000776A2/pt not_active Application Discontinuation
- 2013-07-12 JP JP2015521849A patent/JP6335896B2/ja not_active Expired - Fee Related
- 2013-07-12 CA CA2878868A patent/CA2878868A1/en not_active Abandoned
- 2013-07-12 IN IN350KON2015 patent/IN2015KN00350A/en unknown
- 2013-07-12 US US13/940,834 patent/US9181333B2/en not_active Expired - Fee Related
- 2013-07-12 AU AU2013289990A patent/AU2013289990B2/en not_active Ceased
- 2013-07-12 PE PE2015000037A patent/PE20150360A1/es active IP Right Grant
- 2013-07-12 KR KR1020157003862A patent/KR20150036603A/ko not_active Application Discontinuation
- 2013-07-12 WO PCT/US2013/050300 patent/WO2014012007A2/en active Application Filing
- 2013-07-12 EA EA201590144A patent/EA032038B1/ru not_active IP Right Cessation
- 2013-07-12 EP EP13816428.0A patent/EP2872175A4/en not_active Withdrawn
- 2013-07-12 SG SG11201500233PA patent/SG11201500233PA/en unknown
- 2013-07-12 CN CN201380047332.9A patent/CN104854132A/zh active Pending
- 2013-07-15 TW TW107121349A patent/TW201906861A/zh unknown
- 2013-07-15 TW TW102125212A patent/TWI636061B/zh not_active IP Right Cessation
- 2013-12-07 UA UAA201500865A patent/UA117659C2/uk unknown
-
2015
- 2015-01-11 IL IL236617A patent/IL236617A0/en unknown
- 2015-01-12 NI NI201500002A patent/NI201500002A/es unknown
- 2015-01-13 CL CL2015000097A patent/CL2015000097A1/es unknown
- 2015-01-13 PH PH12015500084A patent/PH12015500084A1/en unknown
- 2015-02-06 ZA ZA2015/00872A patent/ZA201500872B/en unknown
- 2015-02-12 EC ECIEPI20155280A patent/ECSP15005280A/es unknown
- 2015-09-24 HK HK15109369.7A patent/HK1208687A1/xx unknown
- 2015-09-30 US US14/870,145 patent/US9598497B2/en active Active
-
2017
- 2017-02-22 US US15/439,288 patent/US20170267776A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2015000097A1 (es) | Agentes de unión de proteína de r-espondina humana (rspo3) y usos de los mismos. | |
IL286784A (en) | Compositions of protein and antibody | |
BR112015014063A2 (pt) | anticorpos anti-b7-h4 humano e seus usos. | |
CO7071095A2 (es) | Anticuerpos humanos anti-cd27, métodos, y usos | |
CO6821892A2 (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
BR112014019459A2 (pt) | proteínas de ligação à cdim e usos das mesmas | |
CR20150380A (es) | Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico | |
CL2015001924A1 (es) | Anticuerpos anti-pdgfr-beta y usos relacionados. | |
BR112015001459A2 (pt) | anticorpos anti-kit e usos dos mesmos. | |
CO6940383A2 (es) | Anticuerpos anti-erbb3 y usos de los mismos | |
CO7020859A2 (es) | Anticuerpos anti-cd134 (ox40) y usos de los mismos | |
CO7061078A2 (es) | Compuestos de enediino, conjugados de los mismos y sus usos y metodos | |
BR112015002790A2 (pt) | anticorpos asgpr e usos dos mesmos. | |
DK3375324T3 (da) | Skønhedsspejl | |
BR112013007499A2 (pt) | piridazinonas - métodos de criação e usos | |
BR112014020304A8 (pt) | terapêutica para ligação de eritrócitos | |
BR112014000055A2 (pt) | polipeptídeos de fusão de relaxina e usos dos mesmos | |
BR112015011111A2 (pt) | proteína multifuncional e formulação farmacêutica | |
BR112015004817A2 (pt) | bioconjugados compreendendo antígenos modificados e seus usos | |
CL2015001266A1 (es) | Anticuerpos de antihemaglutinina y métodos de uso. | |
CL2014003372A1 (es) | Proteinas fijadoras de antigeno antagonistas del receptor de accion dual y sus usos | |
CL2014002019A1 (es) | Anticuerpos anti - asic1; composicion farmaceutica que lo comprende y usos de los mismos. | |
BR112014000049A2 (pt) | pirrolotriazinas substituídas com hidroximelilarilo e sua utilização | |
BR112014033045A2 (pt) | dispositivo e método para ligação de tecido | |
DK2928505T3 (da) | Positron-emitterende radionuklidmærkede peptider til human upar-pet-billeddannelse |